Correspondence 0001193125-23-239664 from Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)

Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)
Date: Sept. 21, 2023 · CIK: 0001780097 · Accession: 0001193125-23-239664

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-272994

Date

September 21, 2023

Author

Not clearly detected

Form

CORRESP

Company

Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)

Letter

Baudax Bio, Inc.

490 Lapp Rd.

Malvern, Pennsylvania 19355

September 21, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Re: Baudax Bio, Inc.

Registration Statement on Form S-3 (File No. 333-272994)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-272994) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 9:30 AM, eastern time, on September 25, 2023, or as soon as thereafter as is practicable.

Please contact Jennifer Porter, Esq. of Goodwin Procter LLP, counsel to the Company, at (445) 207-7806 to provide notice of effectiveness, or if you have any questions or comments concerning this request.

[Remainder of the page intentionally left blank]

Very truly yours,
BAUDAX BIO, INC.

Show Raw Text

CORRESP
1
filename1.htm

CORRESP

 Baudax Bio, Inc.

490 Lapp Rd.

 Malvern,
Pennsylvania 19355

 September 21, 2023

VIA EDGAR

 U.S. Securities and Exchange Commission

100 F Street, N.E.

 Washington, D.C. 20549

Re:
 Baudax Bio, Inc.

 Registration Statement on Form S-3 (File No. 333-272994)

 Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby
requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-272994) (the “Registration
Statement”) be accelerated so that the Company’s Registration Statement will become effective at 9:30 AM, eastern time, on September 25, 2023, or as soon as thereafter as is practicable.

Please contact Jennifer Porter, Esq. of Goodwin Procter LLP, counsel to the Company, at (445)
207-7806 to provide notice of effectiveness, or if you have any questions or comments concerning this request.

[Remainder of the page intentionally left blank]

 1

 Very truly yours,

BAUDAX BIO, INC.

By:

/s/ Gerri A. Henwood

 Name:  Gerri A. Henwood

 Title:  Chief Executive Officer

 Baudax Bio, Inc.
— Acceleration Letter

SecProbe.io